Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based …
JSG Montaner, VD Lima, R Barrios, B Yip, E Wood… - The Lancet, 2010 - thelancet.com
Background Results of cohort studies and mathematical models have suggested that
increased coverage with highly active antiretroviral therapy (HAART) could reduce HIV …
increased coverage with highly active antiretroviral therapy (HAART) could reduce HIV …
Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” …
Background There has been renewed call for the global expansion of highly active antiretroviral
therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, …
therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, …
The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study
Background The cascade of HIV care has become a focal point for implementation efforts to
maximise the individual and public health benefits of antiretroviral therapy. We aimed to …
maximise the individual and public health benefits of antiretroviral therapy. We aimed to …
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain
incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike …
incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike …
Emergent drug resistance with integrase strand transfer inhibitor-based regimens
Objectives: To estimate the incidence of and risk factors for emergent resistance to integrase
strand transfer inhibitor (INSTI) and nucleoside (-tide) reverse transcriptase inhibitors (NRTI…
strand transfer inhibitor (INSTI) and nucleoside (-tide) reverse transcriptase inhibitors (NRTI…
[HTML][HTML] People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose …
…, CF Lowe, R Pantophlet, MG Romney, R Barrios… - medRxiv, 2022 - ncbi.nlm.nih.gov
Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain
incompletely characterized in people living with HIV (PLWH), as do initial responses to a third …
incompletely characterized in people living with HIV (PLWH), as do initial responses to a third …
Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study
Background We sought to understand whether people living with HIV (PLHIV) ever on highly
active antiretroviral therapy (ART) follow a pattern where morbidity is compressed into the …
active antiretroviral therapy (ART) follow a pattern where morbidity is compressed into the …
Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes
…, E Wood, T Kerr, V Lima, R Barrios… - JAIDS Journal of …, 2010 - journals.lww.com
Highly active antiretroviral therapy (HAART) represents the single most significant advance
in the fight against HIV/AIDS. The vast majority of patients treated with HAART will …
in the fight against HIV/AIDS. The vast majority of patients treated with HAART will …
Adverse drug reactions to integrase strand transfer inhibitors
… Correspondence to Dr Rolando Barrios, BC Centre for Excellence in HIV/AIDS, 1081 Burrard
Street, Vancouver BC, Canada V6Z 1Y6. Tel: +1 604 682 2344 ext. 66338; fax: +1 604 806 …
Street, Vancouver BC, Canada V6Z 1Y6. Tel: +1 604 682 2344 ext. 66338; fax: +1 604 806 …
People with human immunodeficiency virus receiving suppressive antiretroviral therapy show typical antibody durability after dual coronavirus disease 2019 …
…, R Pantophlet, MG Romney, R Barrios… - The Journal of …, 2023 - academic.oup.com
Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19)
vaccines remain incompletely characterized in people living with human …
vaccines remain incompletely characterized in people living with human …
